Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company
23.7.2024 15:00:00 EEST | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced that it has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed contract extends through 2029 with a notable amendment that outlines a purchase commitment for two therapeutic products representing an incremental value of approximately $250 million through the end of the renewed term.
In addition, KBI, in late June, completed a successful regulatory inspection by the U.S. Food and Drug Administration (FDA) of its mammalian operation in Durham, North Carolina. This regulatory inspection enables the company’s North Carolina operations to begin providing a mammalian drug substance commercially to one of its key strategic customers. It also demonstrates KBI’s ability to act as a preferred partner for large volume commercial therapeutic manufacturing.
“As KBI continues fulfilling its commitment to our customers in helping solve their complex manufacturing challenges, this commercial contract extension allows us to demonstrate our approach as a next-generation CDMO,” said J.D. Mowery, President and CEO of KBI Biopharma. “With this agreement as well as our successful FDA regulatory inspection, we’re driving breakthroughs in biopharmaceutical development and manufacturing that help bring new therapies to market.”
He concluded, “By establishing these trusted, long-term partnerships with global pharmaceutical leaders, we’re able to positively impact the lives of patients worldwide.”
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723243720/en/
Contacts
KBI Biopharma, Inc. Company Inquiries
Sarah Wakefield
KBI Biopharma, Inc.
swakefield@kbibiopharma.com
KBI Biopharma, Inc. Media Inquiries
Kelly Biele
CG Life
kbiele@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Heaviside Industries Unveils the TYR Loitering Munition, A Five-Pound Tank-Killer12.10.2026 13:00:00 EEST | Press release
Heaviside Industries, a builder of multi-domain precision munitions platforms, today introduced its TYR miniaturized loitering munition at the AUSA Annual Meeting & Exposition in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012159239/en/ The first in Heaviside’s line of precision munitions, TYR delivers outsized performance for its weight, combining speed, endurance, and lethal effects in a truly man-packable system. Weighing just over five pounds with a total system weight of approximately 15 pounds, TYR can defeat a wide range of targets, including main battle tanks. TYR offers four Nammo warhead variants — Shaped Charge Anti-Tank, Anti-Structure Munition, Explosively Formed Penetrator, and Anti-Personnel Frag — allowing warfighters to tailor lethal effects across multiple mission sets. TYR can be employed in ground and base defense operations, utilized as a counter-UAS system, or integrated onto larg
Navan Selected by Investec to Modernize Global Travel Program12.10.2026 11:00:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Investec, a leading international bank and wealth manager, to upgrade its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009977645/en/ Leading international bank and wealth manager chooses Navan to deliver an AI-first travel program “As Investec continues its digital transformation, we’re excited to partner with an AI-first travel platform to increase adoption and improve operational efficiency,” said Lyndon Subroyen, Investec Group Chief Technology and Operating Officer. As a dual-listed company in the United Kingdom and South Africa, Investec sought a partner to consolidate its travel operations, reduce administrative work, and improve the booking experience for its workforce. Investec needed a solution to increase platform adoption and help employees travel more cost-efficient
Opensignal Launches World’s First Interactive Map of Satellite-to-Smartphone D2D Connections12.10.2026 11:00:00 EEST | Press release
Opensignal, a global independent consumer connectivity analytics and insights company, today launched the Opensignal D2D Satellite Map, the world’s first interactive, real-world depiction of where direct-to-device (D2D) satellite connections with smartphones are happening across the globe. Every point on the map, which will be updated monthly, represents a location where smartphones have connected to a D2D service since January 2026, extracted from Opensignal’s billions of real-world measurements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261011884935/en/ Opensignal D2D Satellite Map “D2D is reshaping who can deliver mobile coverage, and where, because the phone in your pocket can now reach a satellite directly. Until now, the industry has had to make decisions without knowing where momentum and adoption are real,” said Mike Sandy, President, Market Performance at Opensignal. “The Opensignal D2D Satellite Map provides a
Demand for Tech Services in Europe Continues to Surge, Led by AI-Driven Infrastructure Spending in Q3: ISG Index™12.10.2026 11:00:00 EEST | Press release
Surging AI demand propelled Europe’s technology services market to a new high in the third quarter, as infrastructure spending more than doubled and traditional managed services grew by double digits, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, finds. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both managed services and cloud-based infrastructure and software services) soared 56 percent—its fastest growth in eight years—to US $14.9 billion. It was the fourth straight quarter that combined ACV growth has exceeded 20 percent, averaging 39 percent in that span. “The European market is absolutely roaring right now,” said Anthony Drake, president, ISG EMEA. “After surpassing US $10 billion for the first time in last year’s fourth quarter, demand continu
Carta Secures Authorization to Operate as Fund Administrator and Transfer Agent in Luxembourg12.10.2026 11:00:00 EEST | Press release
Carta, the connected platform and AI-native ecosystem for private capital, today announced it has received authorization to operate as a fully-licensed Specialised Professional of the Financial Sector (PSF) under the supervision of the CSSF (Commission de Surveillance du Secteur Financier) in Luxembourg. The authorization covers five statutory functions — registrar agent, corporate domiciliation agent, company incorporation and management services, administrative agent of the financial sector, and client communication agent — adding licensed fund administration and transfer agency directly to a platform already serving Luxembourg fund managers. Luxembourg is the second-largest fund domicile in the world, home to approximately 5,000 alternative investment fund entities managing over €1 trillion in assets. It is also the preferred jurisdiction for over 1,000 US and APAC fund managers running parallel or feeder structures, representing more than $333 billion in AUM. For managers operating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom